Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 17, 2025

Study Completion Date

January 31, 2026

Conditions
Mesopic VisionNight Vision Loss
Interventions
DRUG

phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist

Once daily dosing

DRUG

Placebo

Once daily dosing

Trial Locations (23)

11787

United States Smithtown, Smithtown

24502

United States Lynchburg, Lynchburg

27529

United States, North Carolina, Garner

29464

United States, Mt Pleasant, SC, Mt. Pleasant

32256

United States, Jacksonville, FL, Jacksonville

32257

United States Jacksonville, Jacksonville

33603

United States, Tampa

37167

United States Smyrna, Smyrna

37411

United States Chattanooga, Chattanooga

40206

United States Louisville, Louisville

48026

United States Fraser, Fraser

58103

United States Fargo, Fargo

66210

United States Overland Park, Overland Park

84020

United States Draper, Draper

85003

United States Phoenix, Phoenix

85260

United States Scottsdale, Scottsdale

90505

United States Torrance, Torrance

91204

United States, Glendale, CA, Glendale

91748

United States Rowland Heights, Rowland Heights

92663

United States, California, Newport Beach

92903

United States, LaJolla, CA, La Jolla

93309

United States, Bakersfield

02888

United States, Rhode Island, Warwick

Sponsors
All Listed Sponsors
collaborator

Viatris Inc.

INDUSTRY

lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT06349759 - Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances | Biotech Hunter | Biotech Hunter